Page last updated at 09:53 GMT, Thursday, 23 July 2009 10:53 UK

Roche sales of Tamiflu soar 200%

Tamiflu
The drug has been offered to those with close contact to swine flu

Swiss drugs firm Roche has seen sales of Tamiflu - the main drug being used to fight the swine flu pandemic - rise by 200% in the first half of the year.

Sales of the drug hit 1bn Swiss francs ($937m; £567m), as Roche said Tamiflu production would be expanded to 400 million packs annually by early 2010.

But Roche saw first-half net profits fall by 29% to 4.1bn Swiss francs.

That was mainly due to costs related to the takeover of its California-based partner Genentech.

In March Roche paid $46.8bn to buy the remaining 45% of Genentech that it did not already own.

'Development portfolio'

"I am especially pleased about the excellent progress we've made in integrating Roche and Genentech," said chief executive Severin Schwan.

"Work at Genentech's research and early development centre in South San Francisco has continued seamlessly with the existing management team."

Mr Schwan said the company would be benefiting from the synergies of the merger sooner than originally envisaged.

He also said Roche had one of the the "strongest development portfolios in the industry".



Print Sponsor


SEE ALSO
Flu treatment output 'to triple'
22 Jul 09 |  Business
Roche seals $47bn Genentech deal
12 Mar 09 |  Business
Tamiflu boosts drug firm's profit
07 Feb 07 |  Business

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2013 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific